DK1957539T3 - Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse - Google Patents
Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelseInfo
- Publication number
- DK1957539T3 DK1957539T3 DK06848508.5T DK06848508T DK1957539T3 DK 1957539 T3 DK1957539 T3 DK 1957539T3 DK 06848508 T DK06848508 T DK 06848508T DK 1957539 T3 DK1957539 T3 DK 1957539T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteintyrosinkinase
- ptk7
- monoclonal antibodies
- human monoclonal
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74837305P | 2005-12-08 | 2005-12-08 | |
PCT/US2006/046837 WO2007067730A2 (en) | 2005-12-08 | 2006-12-08 | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1957539T3 true DK1957539T3 (da) | 2013-05-06 |
Family
ID=38123515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06848508.5T DK1957539T3 (da) | 2005-12-08 | 2006-12-08 | Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse |
Country Status (22)
Country | Link |
---|---|
US (3) | US8222375B2 (da) |
EP (1) | EP1957539B1 (da) |
JP (1) | JP5401639B2 (da) |
KR (1) | KR101373464B1 (da) |
CN (1) | CN101360761B (da) |
AU (1) | AU2006321841C1 (da) |
BR (1) | BRPI0619582A2 (da) |
CA (1) | CA2632552C (da) |
DK (1) | DK1957539T3 (da) |
EA (1) | EA017812B1 (da) |
ES (1) | ES2406063T3 (da) |
HK (1) | HK1121174A1 (da) |
IL (1) | IL191788A (da) |
ME (1) | ME02002B (da) |
NO (1) | NO20082559L (da) |
NZ (2) | NZ569236A (da) |
PL (1) | PL1957539T3 (da) |
PT (1) | PT1957539E (da) |
RS (1) | RS52804B (da) |
SG (1) | SG177194A1 (da) |
SI (1) | SI1957539T1 (da) |
WO (1) | WO2007067730A2 (da) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
CA2630483C (en) * | 2005-12-08 | 2015-05-19 | Medarex, Inc. | Human monoclonal antibodies to o8e |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
US7960125B2 (en) * | 2007-09-25 | 2011-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression |
ES2445755T3 (es) * | 2007-11-07 | 2014-03-05 | Celldex Therapeutics, Inc. | Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205) |
AR069903A1 (es) * | 2007-11-30 | 2010-03-03 | Medarex Inc | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer |
WO2009116764A2 (ko) * | 2008-03-17 | 2009-09-24 | 연세대학교 산학협력단 | Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제 |
KR101123130B1 (ko) * | 2008-03-17 | 2012-03-30 | 연세대학교 산학협력단 | Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제 |
RU2562865C2 (ru) | 2009-07-10 | 2015-09-10 | Иннэйт Фарма | Tlr3 связывающие агенты |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
SA112330278B1 (ar) * | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
JP2014532060A (ja) | 2011-10-03 | 2014-12-04 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 癌を治療するためのピロロピリミジン化合物 |
PE20141791A1 (es) | 2012-02-13 | 2014-11-19 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de los mismos y sus usos y metodos |
IN2014DN09610A (da) | 2012-05-22 | 2015-07-31 | Univ North Carolina | |
ES2695151T3 (es) | 2012-05-31 | 2019-01-02 | Innate Pharma | Agentes de ligación a TLR3 |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
MX356698B (es) | 2013-02-14 | 2018-06-11 | Bristol Myers Squibb Co | Compuestos de tubulisina, metodos para obtenerlos y uso. |
AU2014306592B2 (en) | 2013-08-14 | 2019-04-04 | Bristol-Myers Squibb Company | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
CA2945129A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
CN106659801B (zh) * | 2014-04-30 | 2019-12-10 | 辉瑞大药厂 | 抗-ptk7抗体-药物缀合物 |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
PE20180926A1 (es) * | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
CA3008678A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
JOP20170013B1 (ar) | 2016-01-22 | 2021-08-17 | Merck Sharp & Dohme | أجسام xi مضادة لعامل مضاد للتجلط |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
JP2019518013A (ja) | 2016-05-10 | 2019-06-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 安定性が向上したツブリシン類似体の抗体薬物結合体 |
PE20190416A1 (es) | 2016-06-14 | 2019-03-19 | Merck Sharp & Dohme | Anticuerpos antifactor de la coagulacion xi |
JP7023933B2 (ja) | 2016-08-19 | 2022-02-22 | ブリストル-マイヤーズ スクイブ カンパニー | セコ-シクロプロパピロロインドール化合物、その抗体-薬物コンジュゲート、ならびに製造および使用方法 |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
KR20200013241A (ko) | 2017-05-25 | 2020-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
IL312163A (en) | 2018-05-29 | 2024-06-01 | Bristol Myers Squibb Co | Modified atom groups that sacrifice themselves for use in prodrugs and conjugates and methods of use and preparation |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
BR112021008083A2 (pt) * | 2018-11-07 | 2021-08-10 | Crispr Therapeutics Ag | terapia contra o câncer com célula imunológica anti-ptk7 |
CN113348177A (zh) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
SI3886914T1 (sl) | 2018-11-30 | 2023-06-30 | Bristol-Myers Squibb Company | Protitelo, ki vsebuje C-terminalni podaljšek lahke verige, ki vsebuje glutamin, njegove konjugate ter metode in uporabe |
CN113544155A (zh) | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途 |
KR102236127B1 (ko) * | 2019-08-08 | 2021-04-07 | 주식회사 하울바이오 | 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
TW202208412A (zh) * | 2020-05-06 | 2022-03-01 | 瑞士商Crispr治療公司 | 對酪胺酸蛋白激酶樣7(ptk7)特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞 |
WO2022015113A1 (ko) * | 2020-07-16 | 2022-01-20 | 연세대학교 산학협력단 | Ptk7에 특이적으로 결합하는 항체 및 이의 용도 |
CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
CN114213541B (zh) * | 2021-12-20 | 2022-12-30 | 南京诺唯赞生物科技股份有限公司 | 一种全能核酸酶的单克隆抗体及其制备方法 |
WO2023180484A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing ptk7 |
WO2023225639A1 (en) * | 2022-05-19 | 2023-11-23 | Mythic Therapeutics, Inc. | Ptk7-binding proteins with ph-dependent binding and uses thereof |
GB202209196D0 (en) * | 2022-06-22 | 2022-08-10 | Almac Discovery Ltd | Bi-specific antigen binding molecules |
WO2024037621A1 (en) * | 2022-08-19 | 2024-02-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Ptk7-binding protein and use thereof |
WO2024054030A1 (ko) * | 2022-09-06 | 2024-03-14 | 연세대학교 산학협력단 | 항-ptk7 항체 및 이의 용도 |
WO2024080325A1 (ja) * | 2022-10-14 | 2024-04-18 | Jsr株式会社 | 抗体及びその使用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708930A (en) * | 1984-11-09 | 1987-11-24 | Coulter Corporation | Monoclonal antibody to a human carcinoma tumor associated antigen |
AU6238696A (en) * | 1995-05-25 | 1996-12-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders |
EP0862553A4 (en) | 1995-10-03 | 1999-02-03 | Scripps Research Inst | CBI ANALOG OF CC-1065 AND THE DUOCARMYCINES |
AU6887698A (en) | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
CA2290789A1 (en) | 1997-05-22 | 1998-11-26 | Dale L. Boger | Analogs of duocarmycin and cc-1065 |
JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | HER2/neuに対するヒトモノクローナル抗体 |
EP1425302A2 (en) | 2001-01-24 | 2004-06-09 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
EP1463928A2 (en) | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
MXPA03011094A (es) | 2001-05-31 | 2004-12-06 | Medarex Inc | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. |
GB0114033D0 (en) | 2001-06-09 | 2001-08-01 | Innovata Biomed Ltd | Process |
ES2364452T3 (es) | 2001-06-11 | 2011-09-02 | Medarex, Inc. | Método para diseñar compuestos profármacos activados por cd10. |
CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
CA2459308A1 (en) | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
JP2003088388A (ja) | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長cDNA |
WO2003025138A2 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
AU2002362646A1 (en) | 2001-10-09 | 2003-04-22 | The Johns Hopkins University | A phosphatase associated with metastasis |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
DK1461359T3 (da) * | 2002-01-18 | 2007-07-09 | Pf Medicament | Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf |
US20040197792A1 (en) | 2002-07-15 | 2004-10-07 | Sugen, Inc. | Novel Kinases |
GB0219776D0 (en) | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
EP1860186B1 (en) | 2003-03-10 | 2010-11-17 | Japan Science And Technology Agency | Method for distinguishing mesenchymal stem cells using different markers |
AU2004256425A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2005063987A1 (en) | 2003-12-19 | 2005-07-14 | Aveo Pharmaceuticals, Inc. | Gp153: methods and compositions for treating cancer |
JP2007535562A (ja) | 2004-04-29 | 2007-12-06 | ジェンザイム・コーポレイション | 多嚢胞性疾患の処置のための方法および組成物 |
US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
WO2006002203A2 (en) | 2004-06-23 | 2006-01-05 | Genzyme Corporation | Methods and compositions for the treatment of polycystic diseases |
WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
AR069903A1 (es) | 2007-11-30 | 2010-03-03 | Medarex Inc | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
-
2006
- 2006-12-08 SG SG2011090792A patent/SG177194A1/en unknown
- 2006-12-08 PL PL06848508T patent/PL1957539T3/pl unknown
- 2006-12-08 BR BRPI0619582-2A patent/BRPI0619582A2/pt not_active Application Discontinuation
- 2006-12-08 DK DK06848508.5T patent/DK1957539T3/da active
- 2006-12-08 ME MEP-2013-230A patent/ME02002B/me unknown
- 2006-12-08 JP JP2008544528A patent/JP5401639B2/ja not_active Expired - Fee Related
- 2006-12-08 EA EA200801509A patent/EA017812B1/ru not_active IP Right Cessation
- 2006-12-08 KR KR1020087015763A patent/KR101373464B1/ko active IP Right Grant
- 2006-12-08 WO PCT/US2006/046837 patent/WO2007067730A2/en active Application Filing
- 2006-12-08 PT PT68485085T patent/PT1957539E/pt unknown
- 2006-12-08 SI SI200631569T patent/SI1957539T1/sl unknown
- 2006-12-08 US US12/095,986 patent/US8222375B2/en active Active
- 2006-12-08 NZ NZ569236A patent/NZ569236A/en not_active IP Right Cessation
- 2006-12-08 CA CA2632552A patent/CA2632552C/en not_active Expired - Fee Related
- 2006-12-08 AU AU2006321841A patent/AU2006321841C1/en not_active Ceased
- 2006-12-08 ES ES06848508T patent/ES2406063T3/es active Active
- 2006-12-08 RS RS20130230A patent/RS52804B/en unknown
- 2006-12-08 EP EP06848508.5A patent/EP1957539B1/en not_active Revoked
- 2006-12-08 CN CN2006800510578A patent/CN101360761B/zh not_active Expired - Fee Related
- 2006-12-08 NZ NZ594466A patent/NZ594466A/xx not_active IP Right Cessation
-
2008
- 2008-05-28 IL IL191788A patent/IL191788A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082559A patent/NO20082559L/no not_active Application Discontinuation
-
2009
- 2009-02-10 HK HK09101212.1A patent/HK1121174A1/xx not_active IP Right Cessation
-
2012
- 2012-04-09 US US13/442,499 patent/US9505845B2/en active Active
- 2012-05-10 US US13/468,624 patent/US9102738B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1957539T3 (da) | Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse | |
DK1844074T3 (da) | Humane antistoffer og proteiner | |
CY2018013I1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
DK1960434T3 (da) | Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1 | |
DK1664343T3 (da) | Fremgangsmåder og sammensætninger til generering af kimcelle humane antistofgener | |
DK1656391T3 (da) | Modificerede humane IGF-1R antistoffer | |
DK1817055T3 (da) | Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf | |
ATE480567T1 (de) | Hochkonzentrierter antikörper und proteinformulierungen | |
DK1691837T3 (da) | IP-10-antistoffer og anvendelse heraf | |
DK1877090T3 (da) | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf | |
ATE549033T1 (de) | Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper | |
DK1871418T3 (da) | Humaniserede anti-cd70-bindende midler og anvendelser deraf | |
ATE465180T1 (de) | Therapeutische anti-igfr1-antikörper- kombinationen | |
DK2662390T3 (da) | Interferon alpha receptor 1-antistoffer og anvendelse heraf | |
IS7668A (is) | Manngerð mótefni gegn 4-1BB í mönnum | |
DK1830838T3 (da) | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme | |
DK1599504T3 (da) | Modificeret antistof | |
DK1701968T3 (da) | Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling | |
DK1922309T3 (da) | N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf | |
DK1817343T3 (da) | Humane monoklone antistoffer mod humant IL-4 | |
DK1840121T3 (da) | Glycinderivat og anvendelse heraf | |
DK1954713T3 (da) | Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme | |
DK1976884T3 (da) | Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf. | |
DK1768691T3 (da) | Aequorinholdige præparater og fremgangsmåder til anvendelse af samme | |
NO20024223L (no) | Monoklonale antistoffer til den humane LDL-reseptor, deres fremstilling og anvendelse |